Asbesto como carcinógeno ocupacional en Colombia: desde la biología molecular hasta la salud pública

Autores/as

  • Marcela Pérez-Sosa Doctorado en Oncología, Universidad Nacional de Colombia
  • Carol Guarnizo-Herreño
  • Giancarlo Buitrago
  • Ivan Triana
  • Luis Pino

DOI:

https://doi.org/10.35509/01239015.752

Palabras clave:

Asbesto, Carcinógeno, Mesotelioma, Colombia

Resumen

Asbesto es el nombre asignado desde hace décadas a un grupo de materiales fibrosos con múltiples usos comerciales. Todas las formas de asbesto son cancerígenas para el ser humano, pudiendo causar cáncer de pulmón, laringe, ovario, mesotelioma, entre otras enfermedades relacionadas. El 11 de julio de 2019 se promulgó en Colombia la Ley 1968 “Ana Cecilia Niño" que prohíbe explotar, producir, comercializar, importar, distribuir o exportar cualquier variedad de asbesto y de los productos con él elaborados en el territorio nacional. Con el objetivo de generar un panorama amplio sobre el asbesto como carcinógeno ocupacional en Colombia, la presente revisión aborda cuatro ejes fundamentales de interés: los mecanismos moleculares y celulares, la patología molecular, la investigación clínica y la salud pública en Colombia.

Referencias bibliográficas

Nynäs P, Pukkala E, Vainio H, Oksa P. Cancer Incidence in Asbestos-Exposed Workers: An Update on Four Finnish Cohorts. Saf Health Work. 2017;8(2):169-74.

Pira E, Donato F, Maida L, Discalzi G. Exposure to asbestos: past, present and future. J Thorac Dis. 2018;10(Suppl 2):S237-S45.

Abú-Shams K, Pascal I. Características, propiedades, patogenia y fuentes de exposición del asbesto. Anales del Sistema Sanitario de Navarra. 2005;28:7-11.

Accinelli RA, López LM. Asbesto: la epidemia silenciosa. Acta Médica Peruana. 2016;33:138-41.

Bartrip PWJ. History of asbestos related disease. Postgraduate Medical Journal. 2004;80(940):72-6.

Cooke WE. Fibrosis of the lungs due to the inhalation of asbestos dust. Br Med J. 1924;2(3317):147-0.2.

Cooke WE. Pulmonary Asbestosis. Br Med J. 1927;2(3491):1024-5.

McDonald S. Histology of Pulmonary Asbestosis. Br Med J. 1927;2(3491):1025-6.

Stayner L, Welch LS, Lemen R. The Worldwide Pandemic of Asbestos-Related Diseases. Annual Review of Public Health. 2013;34(1):205-16.

Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17(4):260-71.

World Health Organization.Concha-Barrientos M ND, Driscoll T, Steenland N, Punnett L, Fingerhut M et al. Chapter 21. Selected occupational risk factors 2004 [October 5, 2019]. Available from: http://www.who.int/healthinfo/global_burden_disease/cra/en/.

World Health Organization IPoCS. Environmental Health Criteria 203: Chrysotile asbestos.1998. Available from: http://www.inchem.org/documents/ehc/ehc/ehc203.htm.

World Health Organization IPoCS. Programa Internacional de Seguridad de las Sustancias Químicas- Amianto [Available from: https://www.who.int/ipcs/assessment/public_health/asbestos/es/.

Scaff NB. Congreso de la república de Colombia-Proyecto de Ley: “Ana Cecilia Niño” 2019 [Available from: http://leyes.senado.gov.co/proyectos/images/documentos/Textos%20Radicados/proyectos%20de%20ley/2017%20-%202018/PL%20061-17%20Albesto.pdf.

Rehrauer H, Wu L, Blum W, Pecze L, Henzi T, Serre-Beinier V, et al. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations. Oncogene. 2018;37(20):2645-59.

Hylebos M, Op de Beeck K, van den Ende J, Pauwels P, Lammens M, van Meerbeeck JP, et al. Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma. Familial Cancer. 2018;17(4):569-76.

Cui Y, Wang Y, Deng J, Hu G, Dong F, Zhang Q. Chrysotile effects on the expression of anti-oncogene P53 and P16 and oncogene C-jun and C-fos in Wistar rats’ lung tissues. Environmental Science and Pollution Research. 2018;25(23):22378-88.

Heintz NH, Janssen-Heininger YMW, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010;42(2):133-9.

Luis G, Hernández C, Rubio C, Frías I, Gutiérrez A, Hardisson A. Toxicología del asbesto. Cuadernos de Medicina Forense. 2009:207-13.

Case BW, Abraham JL, Meeker G, Pooley FD, Pinkerton KE. Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma. J Toxicol Environ Health B Crit Rev. 2011;14(1-4):3-39.

Mossman BT, Lippmann M, Hesterberg TW, Kelsey KT, Barchowsky A, Bonner JC. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev. 2011;14(1-4):76-121.

Schneider F, Sporn TA, Roggli VL. Asbestos Fiber Content of Lungs With Diffuse Interstitial Fibrosis: An Analytical Scanning Electron Microscopic Analysis of 249 Cases. Archives of Pathology & Laboratory Medicine. 2010;134(3):457-61.

Ospina D, Villegas VE, Rodríguez-Leguizamón G, Rondón-Lagos M. Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos. Cancer Manag Res. 2019;11:4997-5012.

Kumagai-Takei N, Yamamoto S, Lee S, Maeda M, Masuzzaki H, Sada N, et al. Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos. Int J Mol Sci. 2018;19(2):504.

Costa Amaral Isabele C, Joca Francisco JG, Carvalho Leandro VB, Castro Vinicio S, Pereira Natália C, Murata Marcos M, et al. Evaluation of Genotoxic Effects of Asbestos on Occupationally Exposed Workers in Brazil. Biomonitoring2016.

Srivastava RK, Lohani M, Pant AB, Rahman Q. Cyto-genotoxicity of amphibole asbestos fibers in cultured human lung epithelial cell line: Role of surface iron. Toxicology and Industrial Health. 2010;26(9):575-82.

Öner D, Ghosh M, Moisse M, Duca RC, Coorens R, Vanoirbeek JAJ, et al. Global and gene-specific DNA methylation effects of different asbestos fibres on human bronchial epithelial cells. Environment International. 2018;115:301-11.

Kettunen E, Hernandez-Vargas H, Cros M-P, Durand G, Le Calvez-Kelm F, Stuopelyte K, et al. Asbestos-associated genome-wide DNA methylation changes in lung cancer. International Journal of Cancer. 2017;141(10):2014-29.

Sage AP, Martinez VD, Minatel BC, Pewarchuk ME, Marshall EA, MacAulay GM, et al. Genomics and Epigenetics of Malignant Mesothelioma. High Throughput. 2018;7(3):20.

Galani V, Varouktsi A, Papadatos SS, Mitselou A, Sainis I, Constantopoulos S, et al. The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. Cancer Chemotherapy and Pharmacology. 2019;84(2):241-53.

Hiriart E, Deepe R, Wessels A. Mesothelium and Malignant Mesothelioma. J Dev Biol. 2019;7(2):7.

Benedetti S, Nuvoli B, Catalani S, Galati R. Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget. 2015;6(19):16848-65.

Pietrofesa RA, Velalopoulou A, Albelda SM, Christofidou-Solomidou M. Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605). Int J Mol Sci. 2016;17(3):322-.

Singh A, Kukreti R, Saso L, Kukreti S. Oxidative Stress: Role and Response of Short Guanine Tracts at Genomic Locations. Int J Mol Sci. 2019;20(17):4258.

Mesaros C, Worth AJ, Snyder NW, Christofidou-Solomidou M, Vachani A, Albelda SM, et al. Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure. Bioanalysis. 2015;7(9):1157-73.

Wang Y, Jiang Z, Yan J, Ying S. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma. Disease Markers. 2019;2019:10.

Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017;5(11):238-.

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, et al. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. British Journal Of Cancer. 2014;110:2479.

Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, et al. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. Neoplasia. 2017;19(8):637-48.

Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. Journal of Thoracic Oncology. 2016;11(10):1615-26.

Melaiu O, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S246-S52.

Nymark P, Wikman H, Hienonen-Kempas T, Anttila S. Molecular and genetic changes in asbestos-related lung cancer. Cancer Letters. 2008;265(1):1-15.

Ruosaari S, Hienonen-Kempas T, Puustinen A, Sarhadi VK, Hollmén J, Knuutila S, et al. Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients. BMC Med Genomics. 2008;1:55-.

Rodríguez Panadero F. Diagnóstico y tratamiento del mesotelioma pleural maligno. Archivos de Bronconeumología. 2015;51(4):177-84.

Ascoli V, Minelli G, Cozzi I, Romeo E, Carnovale Scalzo C, Ancona L, et al. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach. Pathology - Research and Practice. 2016;212(10):886-92.

Rossi G. Insert: The Dark Side of Mesothelioma. In: Giordano A, Franco R, editors. Malignant Pleural Mesothelioma: Academic Press; 2019. p. 91-7.

Cornelissen R, Aerts JGJV. Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources? J Thorac Dis. 2018;10(Suppl 9):S1084-S7.

Gillezeau CN, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Carcinogenesis. 2019.

Wu L, Dell'Anno I, Lapidot M, Sekido Y, Chan M-L, Kohno M, et al. Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018). Lung Cancer. 2019;127:138-45.

Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015;8(1):35-9.

Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304-S10.

MacLeod N, Chalmers A, O’Rourke N, Moore K, Sheridan J, McMahon L, et al. Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. Journal of Thoracic Oncology. 2015;10(6):944-50.

Van Schil PE, Opitz I, Weder W, De Laet C, Domen A, Lauwers P, et al. Multimodal management of malignant pleural mesothelioma: where are we today? European Respiratory Journal. 2014;44(3):754-64.

Robinson C, Dick IM, Wise MJ, Holloway A, Diyagama D, Robinson BWS, et al. Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. BMC Cancer. 2015;15(1):983.

Lapidot M, Barash U, Vlodavsky I, Pass H. Heparanase inhibitors restrain mesothelioma. Oncotarget. 2018;9(96).

Dell’anno I, Barone E, Lepori I, Migliore L, Agostini S, Melaiu O, et al. PO-220 RAN, a novel and promising gene for malignant pleural mesothelioma. ESMO Open. 2018;3(Suppl 2):A106-A.

Forde PM, Scherpereel A, Tsao AS. Use of Immune Checkpoint Inhibitors in Mesothelioma. Current Treatment Options in Oncology. 2019;20(2):18.

Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC cancer. 2016;16:656-.

du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res. 2019;11:4297-312.

Popat S. LBA91_PR ‘A multicenter randomized Phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma (MPM) – results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-MESO trial’. ESMO- Annals of Oncology, Volume 30, Supplement 5, October 2019.

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A, et al. ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. Journal of Thoracic Oncology. 2020;15(10):e42.

Forde PM, Sun Z, Anagnostou V, Kindler HL, Purcell WT, Goulart BHL, et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. Journal of Clinical Oncology. 2020;38(15_suppl):9003-.

Cely-García MF, Torres-Duque CA, Durán M, Parada P, Sarmiento OL, Breysse PN, et al. Personal exposure to asbestos and respiratory health of heavy vehicle brake mechanics. Journal of Exposure Science & Environmental Epidemiology. 2015;25(1):26-36.

INC. Boletín legislativo y político Junio de 2019 [Available from: https://www.cancer.gov.co/files/libros/archivos/Bolet%C3%ADn%20Asbesto%202019.pdf.

Ramos-Bonilla JP, Cely-García MF, Giraldo M, Comba P, Terracini B, Pasetto R, et al. An asbestos contaminated town in the vicinity of an asbestos-cement facility: The case study of Sibaté, Colombia. Environmental Research. 2019;176:108464.

Kazan-Allen L. Current Asbestos Bans [Available from: http://ibasecretariat.org/alpha_ban_list.php.

Pasetto R, Terracini B, Marsili D, Comba P. Occupational Burden of Asbestos-related Cancer in Argentina, Brazil, Colombia, and Mexico. Annals of Global Health. 2014;80(4):263-8.

Cely-García MF, Sánchez M, Breysse PN, Ramos-Bonilla JP. Personal Exposures to Asbestos Fibers During Brake Maintenance of Passenger Vehicles. Annals of Work Exposures and Health. 2012;56(9):985-99.

Salazar N, Cely-García MF, Breysse PN, Ramos-Bonilla JP. Asbestos Exposure among Transmission Mechanics in Automotive Repair Shops. Annals of Work Exposures and Health. 2014;59(3):292-306.

Cely-García MF, Curriero FC, Giraldo M, Méndez L, Breysse PN, Durán M, et al. Factors Associated With Non-compliance of Asbestos Occupational Standards in Brake Repair Workers. Annals of Work Exposures and Health. 2016;60(8):1020-35.

Cely-García MF, Curriero FC, Sánchez-Silva M, Breysse PN, Giraldo M, Méndez L, et al. Estimation of personal exposure to asbestos of brake repair workers. Journal of Exposure Science & Environmental Epidemiology. 2017;27(4):417-26.

Vimercati L, Cavone D, Lovreglio P, De Maria L, Caputi A, Ferri GM, et al. Environmental asbestos exposure and mesothelioma cases in Bari, Apulia region, southern Italy: a national interest site for land reclamation. Environmental Science and Pollution Research. 2018;25(16):15692-701.

Musti M, Pollice A, Cavone D, Dragonieri S, Bilancia M. The relationship between malignant mesothelioma and an asbestos cement plant environmental risk: a spatial case–control study in the city of Bari (Italy). International Archives of Occupational and Environmental Health. 2009;82(4):489-97.

Cómo citar

[1]
Pérez-Sosa, M., Guarnizo-Herreño, C., Buitrago, G., Triana, I. y Pino, L. 2022. Asbesto como carcinógeno ocupacional en Colombia: desde la biología molecular hasta la salud pública. Revista Colombiana de Cancerología. 26, 2 (jun. 2022), 127–136. DOI:https://doi.org/10.35509/01239015.752.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

2022-06-30

Número

Sección

Artículos de revisión